Heart Test Labs Common Stock & Warrants Now Trading on Nasdaq
Ticker: HSCSW · Form: 8-K · Filed: Jan 25, 2024 · CIK: 1468492
| Field | Detail |
|---|---|
| Company | Heart Test Laboratories, Inc. (HSCSW) |
| Form Type | 8-K |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $5 million |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: exchange-listing, corporate-action, nasdaq
TL;DR
**Heart Test Labs (HSCS) officially listed its stock and warrants on Nasdaq as of Jan 22, boosting visibility.**
AI Summary
Heart Test Laboratories, Inc. (HSCS) announced on January 22, 2024, that its Common Stock and Warrants are now registered on The Nasdaq Stock Market LLC under the trading symbols HSCS and HSCSW, respectively. This 8-K filing confirms the company's compliance with listing requirements and the official commencement of trading on a major exchange. This matters to investors because listing on Nasdaq can increase the stock's visibility, liquidity, and potentially attract more institutional investors, which could positively impact the stock price.
Why It Matters
Listing on Nasdaq enhances Heart Test Laboratories' market presence, potentially leading to increased investor interest and a more liquid trading environment for its shares and warrants.
Risk Assessment
Risk Level: low — This filing primarily reports a positive corporate action (Nasdaq listing) and does not introduce new financial or operational risks.
Analyst Insight
A smart investor would monitor trading volume and analyst coverage for HSCS and HSCSW, as the Nasdaq listing could attract new investors and improve liquidity, potentially leading to price appreciation.
Key Players & Entities
- Heart Test Laboratories, Inc. (company) — the registrant
- Nasdaq Stock Market LLC (company) — the exchange where securities are registered
- HSCS (other) — trading symbol for Common Stock
- HSCSW (other) — trading symbol for Warrants
- January 22, 2024 (date) — date of earliest event reported
Forward-Looking Statements
- Increased trading volume for HSCS and HSCSW due to enhanced visibility on Nasdaq. (HSCS, HSCSW) — medium confidence, target: Q1 2024
- Potential for greater institutional investor interest in Heart Test Laboratories, Inc. shares. (Heart Test Laboratories, Inc.) — medium confidence, target: Q2 2024
FAQ
What is the primary event reported in this 8-K filing by Heart Test Laboratories, Inc.?
The primary event reported is the registration of Heart Test Laboratories, Inc.'s Common Stock and Warrants on The Nasdaq Stock Market LLC, effective January 22, 2024.
What are the trading symbols for Heart Test Laboratories, Inc.'s securities on Nasdaq?
The trading symbol for the Common Stock is HSCS, and the trading symbol for the Warrants is HSCSW, both on The Nasdaq Stock Market LLC.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 22, 2024.
What is Heart Test Laboratories, Inc.'s state of incorporation?
Heart Test Laboratories, Inc. is incorporated in Texas.
What is the business address of Heart Test Laboratories, Inc. as stated in the filing?
The business address of Heart Test Laboratories, Inc. is 550 Reserve Street, Suite 360, Southlake, Texas, 76092.
Filing Stats: 661 words · 3 min read · ~2 pages · Grade level 13.8 · Accepted 2024-01-25 08:59:38
Key Financial Figures
- $5 million — s resulting compliance with the minimum $5 million stockholders’ equity requirement
Filing Documents
- hscs-20240122.htm (8-K) — 47KB
- hscs-ex99_1.htm (EX-99.1) — 158KB
- 0000950170-24-007222.txt ( ) — 361KB
- hscs-20240122.xsd (EX-101.SCH) — 48KB
- hscs-20240122_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. The following unaudited pro forma balance sheet has been prepared to illustrate the impact of a number of events that followed the close of the Company’s second fiscal quarter ended October 31, 2023, including (i) the Company’s receipt of proceeds from various offerings of the Company’s common stock in November and December 2023, (ii) the conversion of loan notes into shares of common stock in November 2023 and (iii) the issuance of common stock to the Icahn School of Medicine at Mount Sinai as consideration for the rights to various license agreements, and the Company’s resulting compliance with the minimum $5 million stockholders’ equity requirement for initial listing on The Nasdaq Capital Market. In that regard, the Company believes that as of the date of this Form 8-K filing, stockholders’ equity exceeds $5 million. The unaudited pro forma balance sheet is based on the Company’s unaudited balance sheet as of October 31, 2023, as contained in the Company's 10-Q for the quarter ended October 31, 2023, filed with the Securities and Exchange Commission on December 14, 2023, adjusted to reflect the subsequent events after the balance sheet date of October 31, 2023, through the date of filing, as set out in Note 9 of the 10-Q, as if the events occurred on October 31, 2023. This unaudited pro forma balance sheet is for informational purposes only, and should be read in conjunction with the more detailed unaudited condensed consolidated financial statements and related notes thereto included in the Company’s Form 10-Q for the quarter ended October 31, 2023.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.  Exhibit No. Description  99.1 Unaudited Pro Forma Balance Sheet of the Company as of October 31, 2023 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEART TEST LABORATORIES, INC. Date: January 25, 2024 By: /s/ Andrew Simpson Name: Title: Andrew Simpson President, Chief Executive Officer, and Chairman of the Board of Directors